According to the report by China Securities and Futures, Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) announced that the shareholder Shanghai Guosheng Capital Management Co., Ltd. - Shanghai Guosheng Haitong Mingqi High-Quality Development Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (referred to as 'Guosheng Haitong Mingqi High-Quality Development Fund') reduced its shareholding by 9,900 shares in the company, and the planned shareholding reduction period has expired.

As of the date of this announcement, the shareholder Guosheng Haitong Mingqi High-Quality Development Fund holds 20.4901 million shares in the company, accounting for 4.999997% of the total share capital of the company. After the shareholding reduction is completed, Guosheng Haitong Mingqi High-Quality Development Fund will no longer be a shareholder holding more than 5% of the company.